Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Urinary Metabolite GWAS Leads to Biomarkers of Kidney Disease

By LabMedica International staff writers
Posted on 04 Feb 2020
The kidneys integrate information from continuous systemic processes related to the absorption, distribution, metabolism and excretion (ADME) of metabolites. More...
Scientists have identified ties between urine metabolite levels and common genetic variants, laying the foundation for a more refined view of human metabolic processes and the tissues in which they take place.

Prior studies suggest that tissues from several key organs, from the liver and kidneys to the blood and intestinal tract, have a part to play in different aspects of ADME. It is suspected that there might be much more to learn about metabolism by testing urine samples in individuals with lower-than-usual metabolite detoxification and transport in the kidney's proximal tubules due to existing kidney conditions.

Scientists from the University of Freiburg (Freiburg, Germany) performed a genome-wide association study (GWAS) involving 1,627 individuals with diminished kidney function, searching for genetic loci coinciding with urine metabolite concentrations. Included in the study were urinary concentrations of 1,172 metabolites. The metabolic GWAS (mGWAS) led to 240 loci with apparent ties to urine metabolite concentrations, while their follow-up fine-mapping and single-cell expression analyses helped focus in on potential disease-causing genes, the cell types involved, and the urinary metabolites that may flag genetic predisposition to kidney disease.

The 240 unique metabolite–locus associations (metabolite quantitative trait loci, mQTLs) that were identified and replicated highlight novel candidate substrates for transport proteins. The identified genes are enriched in ADME-relevant tissues and cell types, and they reveal novel candidates for biotransformation and detoxification reactions. Fine mapping of mQTLs and integration with single-cell gene expression permitted the prioritization of causal genes, functional variants and target cell types. The combination of mQTLs with genetic and health information from 450,000 UK Biobank participants illuminated metabolic mediators, and hence, novel urinary biomarkers of disease risk.

The authors concluded that this comprehensive resource of genetic targets and their substrates is informative for ADME processes in humans and is relevant to basic science, clinical medicine and pharmaceutical studies. The study was published on January 20, 2020 in the journal Nature Genetics.

Related Links:
University of Freiburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.